breast cancer

Zydus Pinkathon announces the 10th Mumbai Edition on December 21, 2025 at MMRDA Grounds, BKC, will engage more than 30,000 women…

Alkem Laboratories has announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment…

A landmark study from the University of Glasgow could pave the way for new treatments to prevent breast cancer metastasis – a…

GlobalData’s latest report, reveals that the increase is partly attributed to higher survival rates of HER2- breast cancer…

The medicine is now indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic breast cancer

TX-478 could potentially address 30-40 per cent of people with hormone-positive breast cancer, building on Lilly's advancements…

Mumbai-based pharma company unveils a decade-long innovation showing over 80 per cent effectiveness in targeting cancer cells with…

HS-20093: A breakthrough ADC poised to redefine second-line SCLC care in China, strengthening Jiangsu Hansoh's oncology leadership…

GlobalData reports the rise in HER2+ breast cancer cases, stressing the importance of cost-effective biosimilars as Zydus and…

The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients